Advertisements

Inovio Pharmaceuticals Inc. (INO) Stock Quote

Detailed Quote for Inovio Pharmaceuticals Inc. (INO)
$ 4.15   0.29 (+7.51%) Volume: 37.23m 4:00 PM EST Feb 14, 2020
After Hours:  $ 4.32   0.17 (+4.10%) Volume: 275.45k 7:59 PM EST Feb 14, 2020
Today 5d 1m 3m 1y more
Last Price
4.15
Change $
0.29
Change %
7.51%
Tick
  
Bid
4.32
Bid Size
2,000
Ask
4.32
Ask Size
7,800
Open
4.39
High
4.50
Low
4.07
Prev Close
3.86
Last Trade
02/14/20
Volume
37.23m
52 Wk Hi
5.9499998
52 Wk Low
1.91499996
Market Cap
420.65m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
101,361,034
EPS (TTM)
-1.20000004
PE Ratio
N/A
Exchange
NGS
News and Media for Inovio Pharmaceuticals Inc. (INO)
Sector News | Topic News
News for Inovio Pharmaceuticals Inc. (INO)
Sun, Feb 16, 2020
1:10 PM Week In Review: Bio-Thera Raises $241 Million In Shanghai STAR IPO For Antibody Portfolio - SeekingAlpha
Fri, Feb 14, 2020
9:19 AM NVDA, ACB among premarket gainers - SeekingAlpha
Thu, Feb 13, 2020
1:52 PM Here's Why Inovio Pharmaceuticals Stock Rocketed Higher Today - Motley Fool
12:41 PM INO, RDFN, SPWR and NUS among midday movers - SeekingAlpha
9:14 AM INO, CRSP among premarket gainers - SeekingAlpha
6:43 AM Coronavirus death toll spikes in China - SeekingAlpha
Mon, Feb 10, 2020
8:01 PM CTI Biopharma Accelerated Review, And Other News: The Good, Bad, And Ugly Of Biopharma - SeekingAlpha
12:56 PM Here's Why Inovio Pharmaceuticals Jumped Higher Today - Motley Fool
9:23 AM Could These 5 Stocks Benefit From the Coronavirus Outbreak? - Motley Fool
9:16 AM TSLA, INO among premarket gainers - SeekingAlpha
6:00 AM Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP) - PR Newswire
6:00 AM Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP) - PR Newswire
Fri, Feb 07, 2020
6:59 PM Inovio -4.1% after amendment to Stifel sales deal - SeekingAlpha
Wed, Feb 05, 2020
3:00 PM NetworkNewsBreaks - Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Beijing Advaccine Partnership Featured in ROTH Equity Research Report - InvestorBrandNetwork
More News for INO >>
Filings for Inovio Pharmaceuticals Inc. (INO)
Wed, Feb 12, 2020
3:00 AM Statement of acquisition of beneficial ownership by individuals - Form SC 13G
3:00 AM Statement of acquisition of beneficial ownership by individuals - Form SC 13G
Tue, Feb 11, 2020
3:00 AM Statement of acquisition of beneficial ownership by individuals - Form SC 13G
Mon, Feb 10, 2020
3:00 AM [Amend] Statement of acquisition of beneficial ownership by individuals - Form SC 13G/A
Fri, Feb 07, 2020
3:00 AM Prospectus [Rule 424(b)(5)] - Form 424B5
3:00 AM Current report pursuant to Section 13 or 15(d) - Form 8-K
More Filings for INO >>

Tags for Inovio Pharmaceuticals Inc.

Research stocks or mutual funds related to Inovio Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to INO. The keywords below have been associated to INO by either user submission or electronic means.

biotechnology company biotech research clinical research software dna vaccines outsourcing clinical trials biotechnology market mmr vaccine scientific research phase iii clinical trials dna vaccination research clinical research combination vaccines vaccine adjuvants clinical trials industry equine vaccines Surgical and Medical Instrument Manufacturing (339112) yellow fever vaccines vaccination biotech travel health biotechnology research physician clinical trials biotechnology careers clinical trials conference immunization clinic medical device clinical trial vaccine dtap vaccine clinical trials europe vaccines immunization vaccine injury dna research gene therapy child vaccine Healthcare vaccine reactions biotechnology consulting hbv vaccine hpv vaccine vaccine transport nci advanced research biotechnology sales the vaccine clinical trials in india inovio biomedical Common Stock clinical trials in oncology clinical trial advertising